







an Open Access Journal by MDPI

Hereditary and Familial Colorectal Cancer

Guest Editors:

Dr. Bryson W. Katona

Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Dr. Peter P. Stanich

The Ohio State University Wexner Medical Center, Columbus, OH, USA

Deadline for manuscript submissions:

31 December 2024

Message from the Guest Editors

Hereditary and familial colorectal cancers represent nearly a guarter of all colorectal cancers diagnosed. This is caused by identifiable pathogenic germline variants in colorectal cancer risk genes, leading to known hereditary colorectal cancer risk syndromes such as Lynch syndrome or familial adenomatous polyposis (FAP), or may be also related to other familial factors that are less well defined. Identification of and germline genetic testing for these high-risk individuals and families is of paramount of allowing importance in terms for syndrome identification and risk stratification. Finally, cancer through lifestyle modifications prevention chemoprevention may have a substantial impact on future cancer risk. This Special Issue of Cancers will be focused on hereditary and familial colorectal cancer, with a focus on identification of high-risk individuals and families, genetic testing, risk assessment, screening implementation and outcomes, and cancer prevention.













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us